(Q35198895)

7 August 2017

1 reference

title

Weight gain profiles of new anti-psychotics: public health consequences (English)

1 reference

7 August 2017

0 references

1 reference

1 reference

Tardieu S

1

1 reference

7 August 2017

Micallef J

series ordinal

2

1 reference

7 August 2017

Gentile S

series ordinal

3

1 reference

7 August 2017

Blin O

series ordinal

4

1 reference

7 August 2017

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

4

1 reference

7 August 2017

issue

3

1 reference

7 August 2017

page(s)

129-138

1 reference

Changes in body mass index for individuals with and without schizophrenia, 1987–1996

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Nucleus Accumbens Dopamine and the Regulation of Effort in Food-Seeking Behavior: Implications for Studies of Natural Motivation, Psychiatry, and Drug Abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

The sympathetic nervous system and obesity: role in aetiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Barriers to progress--the impact of tolerability problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

CYP2D6 polymorphisms and atypical antipsychotic weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Mechanism of the body weight increase induced by systemic sulpiride

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Clozapine and body mass change.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

A review of the effect of atypical antipsychotics on weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Weight gain with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Antipsychotic-induced weight gain and therapeutic response: a differential association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Atypical antipsychotic drug use and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Prevalence of smoking among psychiatric outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1467-789X.2003.00105.X

10.1046/J.1467-789X.2003.00105.X

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference